SB-334867, a selective orexin-1 receptor antagonist, enhances behavioural satiety and blocks the hyperphagic effect of orexin-A in rats

被引:190
|
作者
Rodgers, RJ [1 ]
Halford, JCG
de Souza, RLN
de Souza, ALC
Piper, DC
Arch, JRS
Upton, N
Porter, RA
Johns, A
Blundell, JE
机构
[1] Univ Leeds, Sch Psychol, Leeds LS2 9JT, W Yorkshire, England
[2] Univ Liverpool, Dept Psychol, Liverpool L69 7NZ, Merseyside, England
[3] SmithKline Beecham Pharmaceut, Harlow CM19 5AD, Essex, England
关键词
appetite; behavioural satiety sequence; food intake; microstructural analysis;
D O I
10.1046/j.0953-816x.2001.01518.x
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Intracerebroventricular (i.c.v.) administration of the novel hypothalamic neuropeptide orexin-A stimulates food intake in rats, and delays the onset of behavioural satiety (i.e. the natural transition from feeding to resting). Furthermore, preliminary findings with the selective orexin-1 receptor antagonist, SB-334867, suggest that orexin-A regulation of food intake is mediated via the orexin-1 receptor. At present, however, little is known about either the intrinsic effects of SB-334867 on the normal structure of feeding behaviour, or its effects upon orexin-A-induced behavioural change. In the present study, we have employed a continuous monitoring technique to characterize the effects of SB-334867 (3-30 mg/kg, i.p.) on the microstructure of rat behaviour during a 1-h test with palatable wet mash. Administered alone, SB-334867 (30 mg/kg, but not lower doses) significantly reduced food intake and most active behaviours (eating, grooming, sniffing, locomotion and rearing), while increasing resting. Although suggestive of a behaviourally nonselective (i.e. sedative) action, the structure of feeding behaviour was well-preserved at this dose level, with the reduction in behavioural output clearly attributable to an earlier onset of behavioural satiety. As previously reported, orexin-A (10 mug per rat i.c.v.) stimulated food intake, increased grooming and delayed the onset of behavioural satiety. Pretreatment with SB-334867 dose-dependently blocked these effects of orexin-A, with significant antagonism evident at dose levels (3-10 mg/kg) below those required to produce intrinsic behavioural effects under present test conditions. Together, these findings strongly support the view that orexin-A is involved in the regulation of feeding patterns and that this influence is mediated through the orexin-1 receptor.
引用
收藏
页码:1444 / 1452
页数:9
相关论文
共 50 条
  • [31] Orexin-1 receptor antagonist SB-334867 reduces the acquisition and expression of cocaine-conditioned reinforcement and the expression of amphetamine-conditioned reward
    Hutcheson, Daniel M.
    Quarta, Davide
    Halbout, Briac
    Rigal, Aurelie
    Valerio, Enzo
    Heidbreder, Christian
    BEHAVIOURAL PHARMACOLOGY, 2011, 22 (02): : 173 - 181
  • [32] The orexin-1 receptor antagonist SB-334867 attenuates anxiety in rats exposed to cat odor but not the elevated plus maze: An investigation of Trial 1 and Trial 2 effects
    Staples, Lauren G.
    Cornish, Jennifer L.
    HORMONES AND BEHAVIOR, 2014, 65 (03) : 294 - 300
  • [33] Effect of Orexin A antagonist (SB-334867) infusion into the nucleus accumbens on consummatory behavior and alcohol preference in Wistar rats
    Mayannavar, Santosh
    Rashmi, K. S.
    Rao, Yalla Durga
    Yadav, Saraswati
    Ganaraja, B.
    INDIAN JOURNAL OF PHARMACOLOGY, 2016, 48 (01) : 53 - 58
  • [34] Blockade of orexin receptor type-1 by SB-334867 and activation of orexin receptor type-2 attenuate morphine tolerance in rats
    Ozdemir, Ercan
    Baser, Tayfun
    Taskiran, Ahmet Sevki
    PHYSIOLOGY INTERNATIONAL, 2022, 109 (04) : 457 - 474
  • [35] Orexin receptor type-1 antagonist SB-334867 decreases morphine-induced antinociceptive effect in formalin test
    Azhdari-Zarmehri, Hassan
    Esmaeili, Mohammad-Hossein
    Sofiabadi, Mohammad
    Haghdoost-Yazdi, Hashem
    PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2013, 112 : 64 - 70
  • [36] The orexin-1 receptor antagonist SB-334867 reduces amphetamine-evoked dopamine outflow in the shell of the nucleus accumbens and decreases the expression of amphetamine sensitization
    Quarta, Davide
    Valerio, Enzo
    Hutcheson, Daniel M.
    Hedou, Gael
    Heidbreder, Christian
    NEUROCHEMISTRY INTERNATIONAL, 2010, 56 (01) : 11 - 15
  • [37] The metabolism of the orexin-1 selective receptor antagonist nivasorexant
    Treiber, Alexander
    Seeland, Swen
    Haschimi, Belal
    Weigel, Aude
    Williams, Jodi T.
    Gabillet, Jerome
    XENOBIOTICA, 2024, 54 (03) : 124 - 137
  • [38] SB 334867, a selective orexin receptor type 1 antagonist, elevates seizure threshold in mice
    Socala, Katarzyna
    Szuster-Ciesielska, Agnieszka
    Wlaz, Piotr
    LIFE SCIENCES, 2016, 150 : 81 - 88
  • [39] Hydrolytic instability of the important orexin 1 receptor antagonist SB-334867: Possible confounding effects on in vivo and in vitro studies
    McElhinny, Charles J., Jr.
    Lewin, Anita H.
    Mascarella, S. Wayne
    Runyon, Scott
    Brieaddy, Lawrence
    Carroll, F. Ivy
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (21) : 6661 - 6664
  • [40] The orexin-1 receptor antagonist SB-334867 reverses the depolarization inactivation of A9 and A10 dopamine neurons caused by chronic administration of haloperidol and olanzapine
    Rasmussen, K
    Merchant, K
    Yang, YL
    NEUROPSYCHOPHARMACOLOGY, 2005, 30 : S249 - S249